KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2017.
“Merck delivered solid performance across our broad range of products that address major disease categories and the needs of global health,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “The continued momentum of KEYTRUDA in oncology, along with the strength of the vaccine and other franchises and animal health, helped to drive revenue growth in the quarter.”
